161 related articles for article (PubMed ID: 34490741)
41. Influence of gastric inhibitory polypeptide on pentagastrin-stimulated gastric acid secretion in patients with type 2 diabetes and healthy controls.
Meier JJ; Nauck MA; Kask B; Holst JJ; Deacon CF; Schmidt WE; Gallwitz B
World J Gastroenterol; 2006 Mar; 12(12):1874-80. PubMed ID: 16609993
[TBL] [Abstract][Full Text] [Related]
42. The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial.
Juel CTB; Lund A; Andersen MM; Hansen CP; Storkholm JH; Rehfeld JF; van Hall G; Hartmann B; Wewer Albrechtsen NJ; Holst JJ; Vilsbøll T; Knop FK
Diabetologia; 2020 Jul; 63(7):1285-1298. PubMed ID: 32394228
[TBL] [Abstract][Full Text] [Related]
43. Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans.
Nissen A; Christensen M; Knop FK; Vilsbøll T; Holst JJ; Hartmann B
J Clin Endocrinol Metab; 2014 Nov; 99(11):E2325-9. PubMed ID: 25144635
[TBL] [Abstract][Full Text] [Related]
44. Effects of variations in duodenal glucose load on glycaemic, insulin, and incretin responses in type 2 diabetes.
Ma J; Pilichiewicz AN; Feinle-Bisset C; Wishart JM; Jones KL; Horowitz M; Rayner CK
Diabet Med; 2012 May; 29(5):604-8. PubMed ID: 22004512
[TBL] [Abstract][Full Text] [Related]
45. Effect of synthetic human glucose-dependent insulinotropic polypeptide (hGIP) on the release of insulin in man.
Füessl HS; Yiangou Y; Ghatei MA; Goebel FD; Bloom SR
Eur J Clin Invest; 1990 Oct; 20(5):525-9. PubMed ID: 2124984
[TBL] [Abstract][Full Text] [Related]
46. Glucose dependent insulinotropic polypeptide (GIP) infused intravenously is insulinotropic in the fasting state in type 2 (non-insulin dependent) diabetes mellitus.
Jones IR; Owens DR; Luzio S; Hayes TM
Horm Metab Res; 1989 Jan; 21(1):23-6. PubMed ID: 2647605
[TBL] [Abstract][Full Text] [Related]
47. Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight.
Schou JH; Pilgaard K; Vilsbøll T; Jensen CB; Deacon CF; Holst JJ; Vølund A; Madsbad S; Vaag AA
J Clin Endocrinol Metab; 2005 Aug; 90(8):4912-9. PubMed ID: 15899957
[TBL] [Abstract][Full Text] [Related]
48. Separate and combined effects of long-term GIP and GLP-1 receptor activation in patients with type 2 diabetes: a structured summary of a study protocol for a double-blind, randomised, placebo-controlled clinical trial.
Helsted MM; Gasbjerg LS; Vilsbøll T; Nielsen CK; Forman JL; Christensen MB; Knop FK
BMJ Open; 2023 Feb; 13(2):e065736. PubMed ID: 36849212
[TBL] [Abstract][Full Text] [Related]
49. Role of endogenous glucagon-like peptide-1 enhanced by vildagliptin in the glycaemic and energy expenditure responses to intraduodenal fat infusion in type 2 diabetes.
Xie C; Wang X; Jones KL; Horowitz M; Sun Z; Little TJ; Rayner CK; Wu T
Diabetes Obes Metab; 2020 Mar; 22(3):383-392. PubMed ID: 31693275
[TBL] [Abstract][Full Text] [Related]
50. GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in Hepatocyte Nuclear Factor 1α Mutation Carriers.
Christensen AS; Hædersdal S; Storgaard H; Rose K; Hansen NL; Holst JJ; Hansen T; Knop FK; Vilsbøll T
Diabetes; 2020 Sep; 69(9):1989-2002. PubMed ID: 32518064
[TBL] [Abstract][Full Text] [Related]
51. GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH
Gasbjerg LS; Hartmann B; Christensen MB; Lanng AR; Vilsbøll T; Jørgensen NR; Holst JJ; Rosenkilde MM; Knop FK
Bone; 2020 Jan; 130():115079. PubMed ID: 31622777
[TBL] [Abstract][Full Text] [Related]
52. A supplementary infusion of glucose-dependent insulinotropic polypeptide (GIP) with a meal does not significantly improve the beta cell response or glucose tolerance in type 2 diabetes mellitus.
Jones IR; Owens DR; Vora J; Luzio SD; Hayes TM
Diabetes Res Clin Pract; 1989 Nov; 7(4):263-9. PubMed ID: 2693029
[TBL] [Abstract][Full Text] [Related]
53. Feedback regulation of glucose-dependent insulinotropic polypeptide (GIP) secretion by insulin in conscious rats.
Bryer-Ash M; Cheung A; Pederson RA
Regul Pept; 1994 May; 51(2):101-9. PubMed ID: 8059006
[TBL] [Abstract][Full Text] [Related]
54. The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study.
Deane AM; Chapman MJ; Fraser RJ; Burgstad CM; Besanko LK; Horowitz M
Crit Care; 2009; 13(3):R67. PubMed ID: 19439067
[TBL] [Abstract][Full Text] [Related]
55. The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance.
Knop FK; Vilsbøll T; Højberg PV; Larsen S; Madsbad S; Holst JJ; Krarup T
Regul Pept; 2007 Dec; 144(1-3):123-30. PubMed ID: 17692937
[TBL] [Abstract][Full Text] [Related]
56. Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects.
Meier JJ; Gallwitz B; Kask B; Deacon CF; Holst JJ; Schmidt WE; Nauck MA
Diabetes; 2004 Dec; 53 Suppl 3():S220-4. PubMed ID: 15561915
[TBL] [Abstract][Full Text] [Related]
57. Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals.
Gasbjerg LS; Helsted MM; Hartmann B; Jensen MH; Gabe MBN; Sparre-Ulrich AH; Veedfald S; Stensen S; Lanng AR; Bergmann NC; Christensen MB; Vilsbøll T; Holst JJ; Rosenkilde MM; Knop FK
Diabetes; 2019 May; 68(5):906-917. PubMed ID: 30626611
[TBL] [Abstract][Full Text] [Related]
58. Metformin improves blood glucose by increasing incretins independent of changes in gluconeogenesis in youth with type 2 diabetes.
Cravalho CKL; Meyers AG; Mabundo LS; Courville A; Yang S; Cai H; Dai Y; Walter M; Walter PJ; Sharma S; Chacko S; Cogen F; Magge SN; Haymond MW; Chung ST
Diabetologia; 2020 Oct; 63(10):2194-2204. PubMed ID: 32728891
[TBL] [Abstract][Full Text] [Related]
59. GIP increases adipose tissue expression and blood levels of MCP-1 in humans and links high energy diets to inflammation: a randomised trial.
Gögebakan Ö; Osterhoff MA; Schüler R; Pivovarova O; Kruse M; Seltmann AC; Mosig AS; Rudovich N; Nauck M; Pfeiffer AF
Diabetologia; 2015 Aug; 58(8):1759-68. PubMed ID: 25994074
[TBL] [Abstract][Full Text] [Related]
60. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
Cuthbertson J; Patterson S; O'Harte FP; Bell PM
Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
